Sickle cell disease begins with a single amino acid substitution in hemoglobin, producing hemoglobin S, which polymerizes when oxygen tension falls. The result is the characteristic sickle shape: red blood cells become rigid, lose their deformability, and lodge in capillary beds, causing the ischemic pain known as vaso-occlusive crisis. In pregnancy, this biology collides with profound physiologic change. Plasma volume expands, the coagulation system shifts toward hypercoagulability, and inflammatory mediators rise, all of which can heighten the risk of crises, acute chest syndrome, and venous thrombosis. According to the source report, anemia and episodic pain affect more than half of pregnant individuals with sickle cell disease, preterm delivery occurs in 9 to 45 percent of such pregnancies, and fetal growth restriction appears in roughly 8 to 21 percent of cases.

The statistical backdrop is sobering. In a large United States cross-sectional study cited in the report, preeclampsia occurred in 10.9 percent of deliveries among patients with sickle cell disease, compared with 4.5 percent in controls. Preeclampsia itself is defined by the American College of Obstetricians and Gynecologists as new-onset hypertension after 20 weeks of gestation with proteinuria, or severe features even without proteinuria. Those severe features include systolic blood pressures of at least 160 mmHg or diastolic pressures of at least 110 mmHg, thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or new cerebral or visual symptoms. For a patient whose red cells already struggle to perfuse her tissues, the added vascular insult of preeclampsia creates a dangerous physiological double bind.

The patient in this case arrived at 33 weeks and 2 days of gestation in severe pain from a vaso-occlusive crisis. Her history included type 2 diabetes, obesity, and avascular necrosis of the right knee, a classic sickle cell complication in which bone tissue dies from interrupted blood supply. Her outpatient regimen already included buprenorphine, a partial opioid agonist, along with acetaminophen. Two days later she returned with left thigh pain rated 8 out of 10 despite her medications, and her blood pressure measured 143/90 mmHg. Intravenous hydromorphone provided minimal relief, prompting admission for inpatient pain control. Laboratory evaluation revealed a hemoglobin of 9.6 g/dL and a hematocrit of 26.2 percent, while a venous duplex ultrasound ruled out deep vein thrombosis as the cause of her leg pain.

One of the most technically interesting aspects of the case involved blood banking. The patient’s antibody screen was positive with a complex antibody profile, meaning her immune system carried antibodies that could react against common red cell antigens. Finding compatible packed red blood cells became genuinely difficult, a problem compounded by the fact that transfusion in sickle cell disease carries risks of alloimmunization, in which further antibodies develop, along with transfusion-related infection and iron overload. Rather than waiting for an emergency, the team transfused 4 units of crossmatched blood while the patient was clinically stable, raising her hemoglobin ahead of anticipated delivery-related blood loss. Intraoperative cell salvage, a technique that recovers blood lost during surgery for reinfusion, was planned as a backup but ultimately was not needed.

Then came the preeclampsia. During the admission, the patient developed repeated severe-range systolic blood pressures, documented between 165/86 and 167/90 mmHg. Notably, no proteinuria assessment was documented, but severe-range pressures alone satisfied diagnostic criteria. Her kidney function remained intact, with a creatinine of 0.59 mg/dL, indicating that end-organ damage had not yet taken hold. The team initiated oral nifedipine at 60 mg every 12 hours, a calcium channel blocker that relaxes vascular smooth muscle, and planned intrapartum magnesium sulfate for seizure prophylaxis, the standard safeguard against eclamptic convulsions. Serial fetal growth surveillance continued because both sickle cell disease and diabetes elevate the risk of fetal growth abnormalities, with an estimated fetal weight tracking at the 60th percentile.

The delivery decision arrived at 35 weeks when a biophysical profile score of 4 out of 8 signaled fetal compromise. Induction of labor was attempted, but after 7 hours of oxytocin augmentation, the cervix remained dilated at only 4 centimeters. The patient requested a primary cesarean section. Labor analgesia had been established through an epidural catheter, which the team redosed for surgical anesthesia, the preferred approach because neuraxial techniques avoid the airway manipulation and hemodynamic swings of general anesthesia. However, immediately after delivery the patient reported intense intraoperative pressure, and after discussion, the anesthesiologists converted to general anesthesia using fentanyl, propofol, succinylcholine, and ketamine, with midazolam, morphine, and ketorolac added for maintenance and analgesia. Hemodynamics remained stable through induction and emergence, a critical detail given the fragility of a preeclamptic, recently transfused patient.

The pharmacology threaded through this case reflects the delicate calculus of analgesia in pregnancy. Acetaminophen remains first-line for vaso-occlusive pain, though recent studies have raised questions about possible associations with childhood asthma or neurodevelopmental outcomes. Nonsteroidal anti-inflammatory drugs are avoided late in gestation because they can prematurely close the fetal ductus arteriosus and reduce amniotic fluid. Patients maintained on buprenorphine should continue their therapy through labor to prevent withdrawal, with full opioid agonists such as hydromorphone added for breakthrough pain and neonates observed for withdrawal if exposure is prolonged. A systematic review cited in the report found no definitive regimen for treating sickle cell pain crises in pregnancy, which means care rests on early recognition of triggers, timely analgesia, judicious fluids, and close maternal-fetal monitoring rather than any standardized protocol.

The postpartum course underscored that delivery resolves neither disease. Magnesium sulfate continued for 24 hours, nifedipine continued for blood pressure control, and the patient received 6 weeks of enoxaparin for venous thromboembolism prophylaxis, an important measure because preeclampsia and sickle cell disease both amplify clotting risk. Hematology recommended maintaining hemoglobin above 10 g/dL with transfusion support and continuing high-dose folic acid to support red cell production. Endocrinology discontinued insulin in favor of metformin for the diabetes. The neonate, weighing 2.565 kg, thrived. The authors emphasize that the lesson of this case is coordination: hematology, obstetrics, anesthesiology, palliative care, and endocrinology each held one thread of a clinical picture in which a single misstep, an incompatible transfusion, an uncontrolled pressure, an abrupt withdrawal, could have unraveled everything. As more individuals with sickle cell disease reach childbearing age, cases like this one map the terrain that multidisciplinary teams must navigate.

Subject of Research: Peripartum anesthetic management of pregnancy complicated by sickle cell disease and preeclampsia

Article Title: Peripartum Anesthetic Management of a Patient With Sickle Cell Disease and Preeclampsia

Article References: Dow, M., Srinivasan, A., & Ayad, S. (2026). Peripartum Anesthetic Management of a Patient With Sickle Cell Disease and Preeclampsia. Clinical Case Reports, 14(10), Article e73662. https://doi.org/10.1002/ccr3.73662

Image Credits: AI Generated

DOI: 10.1002/ccr3.73662

Keywords: sickle cell disease, preeclampsia, vaso-occlusive crisis, obstetric anesthesia, cesarean delivery, blood transfusion, magnesium sulfate, buprenorphine, pregnancy complications, epidural analgesia, fetal surveillance, multidisciplinary care

Hydroxyurea has long been the cornerstone disease-modifying therapy for sickle cell anemia, the homozygous HbSS or HbSβ0-thalassemia genotypes that produce the most severe disease course. The drug works partly by reactivating fetal hemoglobin production, reducing the polymerization of sickle hemoglobin that drives red cell sickling, painful crises, and organ damage. Yet despite decades of clinical use, the precise relationship between dose and both clinical benefit and hematologic harm has remained uncertain, particularly across the diverse populations in which the disease is now treated.

To resolve this, the researchers conducted a systematic review and one-stage multilevel dose-response meta-analysis encompassing randomized trials, nonrandomized comparative studies, and longitudinal cohorts of children and adults with sickle cell disease. The quantitative synthesis focused principally on sickle cell anemia, with hydroxyurea dose expressed in mg/kg/day and achieved or maintenance doses preferred over starting doses. The primary benefit outcome was the rate of recurrent vaso-occlusive crises, while the primary safety outcomes were annual risks of severe or treatment-limiting neutropenia and thrombocytopenia, the two cytopenias that most often force dose reductions or discontinuation.

The modeling strategy was unusually rigorous. The team fitted Emax maximum-effect dose-response models as their primary analysis, testing linear and dose-independent alternatives in sensitivity analyses, and prespecified a decision rule requiring predicted annual neutropenia risk of no more than 5 percent and thrombocytopenia risk of no more than 3 percent, with at least an 80 percent simulation-derived probability that both criteria would be met simultaneously. Any eligible dose also had to retain near-optimal crisis control.

The results revealed a striking asymmetry between benefit and risk across the dose range. Empirical support for the primary analysis clustered between 20 and 28 mg/kg/day, and within that window recurrent vaso-occlusive crisis rates continued to fall, from a predicted 39.8 events per 100 person-years at 20 mg/kg/day to 32.5 at 28 mg/kg/day. Critically, the data showed no efficacy plateau: the Emax ED50 hit the upper limit of the prespecified search grid, and a simpler linear model actually fit marginally better, suggesting that whatever additional crisis reduction higher doses confer had not yet been exhausted within the observed range.

Safety told a different story. Predicted annual risk of severe or treatment-limiting neutropenia climbed steeply and early, from 1.98 percent at 20 mg/kg/day to 3.74 percent at just 21.5 mg/kg/day and 5.63 percent at 22.5 mg/kg/day. Thrombocytopenia, by contrast, remained uncommon and showed little dose dependence. Under the prespecified joint safety rule, the probability that both criteria were met was 87.1 percent at 20 mg/kg/day, 85.6 percent at 21 mg/kg/day, but only 77.8 percent at 21.5 mg/kg/day, failing the 80 percent threshold. The authors cautioned that because safety evidence was sparse and the joint classification depended partly on the relation between the two safety models, the low-20-mg/kg/day range should be read as an approximate safety transition rather than a precise toxicity threshold.

Within the empirically supported range, the lowest modeled recurrent crisis rate occurred at 28 mg/kg/day, and the unconstrained composite-benefit maximum at 25.5 mg/kg/day, but neither could clear the safety bar. Twenty-one mg/kg/day emerged as the highest dose satisfying the analytical rule, and the rounder conventional increment of 20 mg/kg/day was selected as the population reference dose, chosen from standard 2.5-mg/kg/day increments for practical prescribing.

The certainty of evidence behind these estimates was graded as very low for all three outcomes—recurrent crises, neutropenia, and thrombocytopenia—underscoring how much uncertainty remains. The review was prospectively registered with PROSPERO, and the authors emphasize that their decision framework, rather than any single trial, is what allows conflicting and sparse evidence to be converted into an actionable population-level recommendation.

Perhaps the most important clinical message is what the reference dose is not. The authors explicitly state that 20 mg/kg/day is neither a maximum tolerated dose nor a ceiling for treatment. Because crisis rates kept declining above 20 mg/kg/day, higher doses may well be appropriate for individual patients who need further clinical benefit, provided hematologic tolerance, adherence, and laboratory monitoring permit careful escalation. In resource-limited settings where laboratory surveillance is constrained, however, the population-level framework offers a defensible default that maximizes expected benefit while keeping predicted severe cytopenia risks within prespecified limits.

For the millions of people living with sickle cell anemia worldwide, most of them in sub-Saharan Africa, the findings translate decades of fragmented trial evidence into a single, transparent, quantitatively justified starting point for therapy—and a clear signal that the field still needs better safety data to push the benefit curve further.

Subject of Research: Dose-response relationship of hydroxyurea therapy in sickle cell anemia

Article Title: Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment

Article References: Paasi, G., Malaika, N., Ongodia, P., Amorut, D., & Olupot-Olupot, P. (2026). Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07679-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07679-5

Keywords: hydroxyurea, sickle cell anemia, dose-response meta-analysis, vaso-occlusive crisis, neutropenia, thrombocytopenia, benefit-risk assessment, systematic review, fetal hemoglobin, pediatric hematology, BMC Pediatrics, drug dosing